1. Home
  2. VIGL vs RFM Comparison

VIGL vs RFM Comparison

Compare VIGL & RFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VIGL
  • RFM
  • Stock Information
  • Founded
  • VIGL 2020
  • RFM 2020
  • Country
  • VIGL United States
  • RFM United States
  • Employees
  • VIGL N/A
  • RFM N/A
  • Industry
  • VIGL Biotechnology: Pharmaceutical Preparations
  • RFM Finance/Investors Services
  • Sector
  • VIGL Health Care
  • RFM Finance
  • Exchange
  • VIGL Nasdaq
  • RFM Nasdaq
  • Market Cap
  • VIGL 89.3M
  • RFM 92.3M
  • IPO Year
  • VIGL 2022
  • RFM N/A
  • Fundamental
  • Price
  • VIGL $2.76
  • RFM $15.60
  • Analyst Decision
  • VIGL Strong Buy
  • RFM
  • Analyst Count
  • VIGL 5
  • RFM 0
  • Target Price
  • VIGL $21.00
  • RFM N/A
  • AVG Volume (30 Days)
  • VIGL 2.7M
  • RFM 20.7K
  • Earning Date
  • VIGL 03-25-2025
  • RFM 01-01-0001
  • Dividend Yield
  • VIGL N/A
  • RFM 9.74%
  • EPS Growth
  • VIGL N/A
  • RFM N/A
  • EPS
  • VIGL N/A
  • RFM N/A
  • Revenue
  • VIGL N/A
  • RFM N/A
  • Revenue This Year
  • VIGL N/A
  • RFM N/A
  • Revenue Next Year
  • VIGL N/A
  • RFM N/A
  • P/E Ratio
  • VIGL N/A
  • RFM N/A
  • Revenue Growth
  • VIGL N/A
  • RFM N/A
  • 52 Week Low
  • VIGL $1.49
  • RFM $12.89
  • 52 Week High
  • VIGL $6.06
  • RFM $16.41
  • Technical
  • Relative Strength Index (RSI)
  • VIGL 70.15
  • RFM 58.58
  • Support Level
  • VIGL $2.54
  • RFM $15.44
  • Resistance Level
  • VIGL $2.88
  • RFM $15.74
  • Average True Range (ATR)
  • VIGL 0.22
  • RFM 0.11
  • MACD
  • VIGL 0.03
  • RFM 0.03
  • Stochastic Oscillator
  • VIGL 85.19
  • RFM 67.80

About VIGL Vigil Neuroscience Inc.

Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.

About RFM RiverNorth Flexible Municipal Income Fund Inc.

RiverNorth Flexible Municipal Income Fund Inc is a diversified, closed-end management investment company. Its primary investment objective is to seek current income exempt from regular U.S. federal income taxes. The fund's secondary investment objective is total return.

Share on Social Networks: